FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to
Editor’s Note: Patient Worthy is honored to share Michelle Patidar’s patient story, provided to us by our friends at Elephants & Tea. To see the
My chronic health journey is super complicated. When I first started experiencing my symptoms I wouldn’t tell anyone what I was feeling. I would wake
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet,
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH),
CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic
As reported on PharmaBiz, Amneal Pharmaceuticals, in collaboration with mAbxience, has received U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars: Boncresa (referencing
As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement
In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard
Researchers at Oregon Health & Science University have made a significant breakthrough in the fight against acute myeloid leukaemia (AML), discovering that combining a standard
I’ve always known that I wanted to help people. Growing up as the son of a veterinarian and a high school teacher who later became
Iowa University researchers at its Children’s Hospital led the effort that found a new target. According to the Iowa Carver College of Medicine, to date,
Editor’s Note: The following study results were first published in Nephrology Dialysis Transplantation (December 16, 2025) and later shared in the Oxford Academic. The original
Otsuka has claimed a significant victory in the increasingly competitive immunoglobulin A nephropathy (IgAN) field with FDA accelerated approval of Voyxact, the first-in-class anti-APRIL biologic
As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with
Cystic fibrosis affects daily life in ways most people never see. Awareness helps bring visibility to those realities, builds understanding, and supports continued research and access to care. The more people know about CF, the stronger the support becomes for those living with it — now and in the future. #cysticfibrosis #CF #RareDisease #PatientWorthy
Shenqi Dihuang, a traditional Chinese medicine historically used to treat kidney ailments, may be an effective treatment for IgA Nephropathy, according to a recent study. Read more here:
patientworthy.com/2026/01/28/how-shenqi-dihuang-decoction-may-target-key-pathways-in-iga-nephropa...
We're proud to share another article from our friend Tom Seaman, this time about the value of living with challenges. Read here:
patientworthy.com/2026/01/28/the-value-of-living-with-tremendous-challenges/
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
